GlassScriptPhysician profile
Laura Lynn Willis
NPI 1700503604
$1,977.02
in general payments reported to CMS, 2019-2025
23 companies · $568 in 2025
The $568 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.94 · 2023: $477 · 2024: $919 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $399.27 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $241.18 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $209.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $148.57 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.31 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $139.80 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.39 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $81.88 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $55.91 | 2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $55.38 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Intuitive Surgical, INC. | $50.00 | 2023 | Da Vinci Surgical System |
| Radius Health, INC. | $49.54 | 2024-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $48.52 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $39.87 | 2023-2024 | Steglatro, Belsomra, Gardasil 9 |
| Dexcom, INC. | $37.75 | 2024 | Dexcom G6 Transmitter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $36.58 | 2025 | Auvelity |
| Axonics, INC. | $36.44 | 2024 | Axonics |
| Ironshore Pharmaceuticals INC. | $33.81 | 2023-2024 | Jornay Pm |
| Seqirus USA INC | $19.66 | 2025 | Flucelvax, Fluad |
| Cipher Pharmaceuticals US LLC | $18.40 | 2025 | Spinosad, Natroba |
| Dynavax Technologies Corporation | $17.13 | 2024 | Heplisav-B |
| Ibsa Pharma INC. | $14.95 | 2024 | Licart, Tirosint |
| Phathom Pharmaceuticals, INC. | $13.23 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.